← All trials
NCT03509662
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Jun 1, 2021
- Completion date
- Jun 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 270
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Free University of AmsterdamLead sponsor
- Free University of AmsterdamReponsible party - principal investigator
- Free University of AmsterdamStudy director
- Amphia Hospital Breda, the NetherlandsCollaborator
- Erasmus University RotterdamCollaborator
- Maastricht UniversityCollaborator
- Sint Franciscus GasthuisCollaborator
- Gelderse Vallei HospitalCollaborator
- Noordwest ZiekenhuisgroepCollaborator
- TergooiziekenhuizenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.